Recovery of Bupivacaine or Bupivacaine-Lidocaine Spinal Anesthesia and Infiltration Anesthesia in Herniorrhaphy
A Comparison of the Recovery Profiles of Bupivacaine or Bupivacaine Mixed With Lidocaine Spinal Anesthesia and Local Infiltration Anesthesia for Outpatient Herniorrhaphy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey, 06610
- Diskapi Yildirim Beyazit Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients having inguinal hernia
- Not hypersensitive to study drugs
- ASA classification I-III
Exclusion Criteria:
- ASA classification IV-V
- Contraindications for spinal anesthesia
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Bupivacaine(Group B)
spinal anesthesia
|
To receive 2 ml heavy bupivacaine + 0,6 ml saline
Other Names:
To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
Other Names:
|
|
EXPERIMENTAL: Bupivacaine+Lidocaine (Group BL)
spinal anesthesia
|
To receive 2 ml heavy bupivacaine + 0,6 ml saline
Other Names:
To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
Other Names:
|
|
ACTIVE_COMPARATOR: Local Infitration Anesthesia(Group LI)
local infiltration anesthesia
|
To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of spinal block
Time Frame: day of surgery
|
Time between the onset of the sensorial block at L1 dermatome and the resolution of the sensorial block at S3 dermatome.
|
day of surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Discharge time
Time Frame: Day of surgery
|
The time between the end of surgery and home discharge.
|
Day of surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dilek Yazicioglu
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathological Conditions, Anatomical
- Hernia, Abdominal
- Hernia
- Hernia, Inguinal
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Anesthetics
- Lidocaine
- Bupivacaine
Other Study ID Numbers
Other Study ID Numbers
- DiskapiTRHDYAZICIOGLU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.